UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 17, 2005
(Date of earliest event reported)
LABORATORY CORPORATION
OF
AMERICA HOLDINGS
| DELAWARE | 1-11353 | 13-3757370 | ||
| (State or other jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA |
27215 | 336-229-1127 | ||
| (Address of principal executive offices) | (Zip Code) |
(Registrant's telephone number including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
On May 17, 2005 — Laboratory Corporation of America® Holdings (LabCorp®) announced that Thomas P. Mac Mahon, Chairman and Chief Executive Officer, is scheduled to speak at the Banc of America Securities Healthcare Conference in Las Vegas, NV on Thursday, May 19, 2005 at 11:00 a.m. Eastern Time.
Exhibits
99.1 Press Release dated May 17, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Laboratory Corporation of America Holdings (Registrant) |
||||
| Date: May 18, 2005 | By: | /s/Bradford T. Smith | ||
| Bradford T. Smith, Executive Vice President and Secretary |
||||
Exhibit 99.1
Laboratory Corporation of
America® Holdings
358 South Main Street
Burlington, NC 27215
Telephone:(336) 584-5171
FOR IMMEDIATE RELEASE
Contact:
Scott Fleming
336-436-4879
Investor@labcorp.com
Shareholder Direct:
(800)LAB-0401
www.labcorp.com
LABCORP®
SCHEDULED TO PRESENT AT THE
BANC OF AMERICA
SECURITIES HEALTHCARE CONFERENCE
Burlington, NC, May 17, 2005 — Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that Thomas P. Mac Mahon, Chairman and Chief Executive Officer, is scheduled to speak at the Banc of America Securities Healthcare Conference in Las Vegas, NV on Thursday, May 19, 2005 at 11:00 a.m. Eastern Time.
A live audio webcast of the presentation will be available via the Company web site at www.labcorp.com. An archived replay of the audio webcast will be available through June 3, 2005.
About LabCorp
Laboratory Corporation of
America® Holdings, an S&P 500 company with a BBB investment-grade credit rating,
is a pioneer in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $3.1 billion in 2004, approximately
24,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays
ranging from blood analyses to HIV and genomic testing. LabCorp combines its expertise in
innovative clinical testing technology with its Centers of Excellence: The Center for
Molecular Biology and Pathology, in Research Triangle Park, NC; National Genetics
Institute, Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based in Minneapolis, MN;
The Center for Esoteric Testing in Burlington, NC; DIANON Systems, Inc. based in
Stratford, CT, US LABS based in Irvine, CA, and Esoterix and its Colorado Coagulation,
Endocrine Sciences, and Cytometry Associates laboratories. LabCorp clients include
physicians, government agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our growing organization, visit our web site
at: www.LabCorp.com.
Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp’s financial results is included in the Company’s Form 10-K for the year ended December 31, 2004 and subsequent SEC filings.